Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Aurora, CO
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
New Haven, CT
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Boston, MA
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
New Brunswick, NJ
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Nashville, TN
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Dallas, TX
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Houston, TX
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
San Antonio, TX
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Salt Lake City, UT
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Combined Colon and Endometrial Cancer Screening in Women With HNPCC
A Pilot Study for Combined Colon and Endometrial Cancer Screening in Women at High-Risk for Colon and Endometrial Cancer
Status: Enrolling
Updated:  2/15/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Combined Colon and Endometrial Cancer Screening in Women With HNPCC
A Pilot Study for Combined Colon and Endometrial Cancer Screening in Women at High-Risk for Colon and Endometrial Cancer
Status: Enrolling
Updated: 2/15/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Cedars Sinai Medical Center SC
mi
from
Los Angeles, CA
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Cedars Sinai Medical Center SC
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
University of California San Francisco UCSF (SC)
mi
from
San Francisco, CA
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
University of California San Francisco UCSF (SC)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
H. Lee Moffitt Cancer Center & Research Institute Moffitt 4
mi
from
Tampa, FL
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
H. Lee Moffitt Cancer Center & Research Institute Moffitt 4
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Dana Farber Cancer Institute Dana SC
mi
from
Boston, MA
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Dana Farber Cancer Institute Dana SC
mi
from
Boston, MA
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Mayo Clinic - Rochester Division of Hematology
mi
from
Rochester, MN
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Mayo Clinic - Rochester Division of Hematology
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Duke University Medical Center Duke - Baker
mi
from
Durham, NC
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Duke University Medical Center Duke - Baker
mi
from
Durham, NC
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Willamette Valley Clinical Studies Williamette Valley Cancer
mi
from
Eugene, OR
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Willamette Valley Clinical Studies Williamette Valley Cancer
mi
from
Eugene, OR
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Fox Chase Cancer Center FCCC
mi
from
Philadelphia, PA
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Fox Chase Cancer Center FCCC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Sammons Cancer Center - Texas Oncology SC-2
mi
from
Dallas, TX
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Sammons Cancer Center - Texas Oncology SC-2
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
University of Texas/MD Anderson Cancer Center SC-3
mi
from
Houston, TX
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
University of Texas/MD Anderson Cancer Center SC-3
mi
from
Houston, TX
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Northwest Cancer Specialists Northwest Cancer
mi
from
Portland, OR
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Northwest Cancer Specialists Northwest Cancer
mi
from
Portland, OR
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Texas Oncology Midtown Texas Oncology
mi
from
Dallas, TX
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Texas Oncology Midtown Texas Oncology
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Novartis Investigative Site
mi
from
Parkville,
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Novartis Investigative Site
mi
from
Parkville,
Click here to add this to my saved trials
Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
Status: Enrolling
Updated:  2/19/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
Status: Enrolling
Updated: 2/19/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
A Phase II Trial of Lapatinib and Capectiabine for Patients With Refractory Advanced Colorectal Adenocarcinoma (LAP109859)
Status: Enrolling
Updated:  2/19/2016
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
A Phase II Trial of Lapatinib and Capectiabine for Patients With Refractory Advanced Colorectal Adenocarcinoma (LAP109859)
Status: Enrolling
Updated: 2/19/2016
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting
Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting
Status: Enrolling
Updated:  2/25/2016
Kaiser Permanente Northwest
mi
from
Portland, OR
Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting
Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting
Status: Enrolling
Updated: 2/25/2016
Kaiser Permanente Northwest
mi
from
Portland, OR
Click here to add this to my saved trials
Genetic Epidemiology Risk Assessment Program or Usual Care in Colorectal Cancer Screening for Healthy Participants
Gene Environment Risk Assessment and CRC Screening
Status: Enrolling
Updated:  3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Genetic Epidemiology Risk Assessment Program or Usual Care in Colorectal Cancer Screening for Healthy Participants
Gene Environment Risk Assessment and CRC Screening
Status: Enrolling
Updated: 3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes
Status: Enrolling
Updated:  3/1/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes
Status: Enrolling
Updated: 3/1/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
Efficacy and Feasibility of a Psychosocial Intervention Within the CCOP Context: Evaluation of the Facing Forward Guide to Facilitate Life After Active Cancer Treatment
Status: Enrolling
Updated:  3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
Efficacy and Feasibility of a Psychosocial Intervention Within the CCOP Context: Evaluation of the Facing Forward Guide to Facilitate Life After Active Cancer Treatment
Status: Enrolling
Updated: 3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated:  3/3/2016
Clinical Research Facility
mi
from
Bakersfield, CA
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated: 3/3/2016
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated:  3/3/2016
Clinical Research Facility
mi
from
Colorado Springs, CO
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated: 3/3/2016
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated:  3/3/2016
Clinical Research Facility
mi
from
Washington,
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated: 3/3/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated:  3/3/2016
Clinical Research Facility
mi
from
Terre Haute, IN
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated: 3/3/2016
Clinical Research Facility
mi
from
Terre Haute, IN
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated:  3/3/2016
Clinical Research Facility
mi
from
St Louis, MO
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated: 3/3/2016
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated:  3/3/2016
Clinical Research Facility
mi
from
Billings, MT
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated: 3/3/2016
Clinical Research Facility
mi
from
Billings, MT
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated:  3/3/2016
Clinical Research Facility
mi
from
Nyack, NY
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated: 3/3/2016
Clinical Research Facility
mi
from
Nyack, NY
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated:  3/3/2016
Clinical Research Facility
mi
from
Dallas, TX
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated: 3/3/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated:  3/3/2016
mi
from
Bruxelles,
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Status: Enrolling
Updated: 3/3/2016
mi
from
Bruxelles,
Click here to add this to my saved trials
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated:  3/4/2016
UCLA
mi
from
Los Angeles, CA
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated: 3/4/2016
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated:  3/4/2016
Montefiore Medical Center
mi
from
Bronx, NY
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated: 3/4/2016
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated:  3/4/2016
Cleveland Clinic Hospital
mi
from
Cleveland, OH
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated: 3/4/2016
Cleveland Clinic Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated:  3/4/2016
Rhode Island Hospital
mi
from
Providence, RI
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated: 3/4/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Regorafenib + Panitumumab for Colorectal Cancers
Combination Study of Panitumumab and Regorafenib in Advanced or Metastatic KRAS and NRAS Wild Type Colorectal Cancers
Status: Enrolling
Updated:  3/7/2016
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Regorafenib + Panitumumab for Colorectal Cancers
Combination Study of Panitumumab and Regorafenib in Advanced or Metastatic KRAS and NRAS Wild Type Colorectal Cancers
Status: Enrolling
Updated: 3/7/2016
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Beverly Hills, CA
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Santa Maria, CA
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Denver, CO
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Miami, FL
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Ocala, FL
Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials